Research biopsies in the context of early phase oncology studies: clinical and ethical considerations

Main Article Content

Matilde Saggese
Divyanshu Dua
Emily Simmons
Charlotte Lemech
Hendrik-Tobias Arkenau | Tobias.Arkenau@hcahealthcare.co.uk

Abstract

The Personalized Medicine approach in oncology is a direct result of an improved understanding of complex tumor biology and advances in diagnostic technologies. In recent years, there has been an increased demand for archival and fresh tumor analysis in early clinical trials to foster proof-of-concept biomarker development, to understand resistance mechanisms, and ultimately to assess biological response. Although phase I studies are aimed at defining drug safety, pharmacokinetics, and to recommend a phase II dose for further testing, there is now increasing evidence of mandatory tumor biopsies even at the earliest dose-finding stages of drug development. The increasing demand for fresh tumor biopsies adds to the complexity of novel phase I studies and results in different challenges, ranging from logistical support to ethical concerns. This paper investigates key issues, including patients’ perceptions of research biopsies, the need for accurate informed consent, and alternative strategies that may guide the drug development process.

Downloads month by month

Downloads

Download data is not yet available.

Article Details

How to Cite
Saggese, M., Dua, D., Simmons, E., Lemech, C., & Arkenau, H.-T. (2013). Research biopsies in the context of early phase oncology studies: clinical and ethical considerations. Oncology Reviews, 7(1), e5. https://doi.org/https://doi.org/10.4081/oncol.2013.e5
Author Biographies

Matilde Saggese, Sarah Cannon Research UK; University College London

Drug Development Unit

Divyanshu Dua, Sarah Cannon Research UK; Guy’s and St Thomas’ Hospital, London

Drug Development Unit

Emily Simmons, University College London

Drug Development Unit

Charlotte Lemech, Sarah Cannon Research UK; University College London

Drug Development Unit

Hendrik-Tobias Arkenau, Sarah Cannon Research UK; University College London

Drug Development Unit